Review article: Pharmacological treatment of hepatorenal syndrome

Alimentary Pharmacology and Therapeutics

Volumn 20, Issue SUPPL. 3, 2004, Pages 57-62

  Gines P ^a   Torre, A ^a   Terra, C ^a   Guevara, M ^a  

^a HOSPITAL CLÍNIC   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ALPHA ADRENERGIC RECEPTOR; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; CREATININE; DOPAMINE; MIDODRINE; NORADRENALIN; OCTREOTIDE; ORNIPRESSIN; TERLIPRESSIN; VASOCONSTRICTOR AGENT; VASOPRESSIN; VASOPRESSIN DERIVATIVE; VASOPRESSIN RECEPTOR;

ABDOMINAL CRAMP; ARTERY DISEASE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONFERENCE PAPER; DIARRHEA; DISEASE CLASSIFICATION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; GLOMERULUS FILTRATION RATE; HEPATORENAL SYNDROME; HUMAN; ISCHEMIC HEART DISEASE; KIDNEY CIRCULATION; KIDNEY FAILURE; KIDNEY FUNCTION; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; OUTCOMES RESEARCH; PATHOPHYSIOLOGY; PATIENT SELECTION; PORTOSYSTEMIC ANASTOMOSIS; PRIORITY JOURNAL; PROGNOSIS; SPLANCHNIC BLOOD FLOW; SURVIVAL RATE; VASODILATATION;

EID: 4644363216     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2004.02115.x     Document Type: Conference Paper

References (41)

1. Ginès P, Guevara M, Arroyo V, Rodés J. Hepatorenal syndrome. Lancet 2003; 362: 1819-27.
2. Ginès P, Rodés J. Clinical disorders of renal function in cirrhosis with ascites. In: Arroyo, V, Ginès, P, Rodés, J, et al, eds. Ascites and Renal Dysfunction in Liver Disease. Pathogenesis, Diagnosis and Treatment. Maiden: Blackwell Science 1999, 36-62.
3. Arroyo V, Colmenero J. Ascites and hepatorenal syndrome in cirrhosis: pathophysiological basis of therapy and current management. J Hepatol 2003; 38 (Suppl. 1): S69-89.
4. Arroyo V, Ginès P, Gerbes A, et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. Hepatology 1996; 23: 164-76.
5. Schrier RW, Arroyo V, Bernardi M, Epstein M, Henriksen JH, Rodes J. Peripheral arterial vasodilation hypothesis. A proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology 1988; 8: 1151-7.
6. Folio A, Llovet JM, Navasa M, et al. Renal impairment after spontaneous bacterial peritonitis in cirrhosis: incidence, clinical course, predictive factors and prognosis. Hepatology 1994; 20: 495-501.
7. Papper S. Hepatorenal syndrome. In: Epstein, M, ed. The Kidney in Liver Diseases, 2nd edn. New York: Elsevier Biomedical 1983, 87-106.
8. Hecker R, Sherlock S. Electrolyte and circulatory changes in terminal liver failure. Lancet 1956; 271: 1121-5.
9. Epstein M, Berk DP, Hollenberg NK, et al. Renal failure in the patient with cirrhosis. The role of active vasoconstriction. Am J Med 1970; 49: 175-85.
10. Schroeder ET, Shear L, Sancetta SM, Gabuzda GJ. Renal failure in patients with cirrhosis of the liver. Evaluation of intrarenal blood flow by para-aminohippurate extraction and response to angiotensin. Am J Med 1967; 43: 887-96.
11. Kew MC, Brunt PW, Varma RR, Hourigan KJ, Williams HS, Sherlock S. Renal and intrarenal blood-flow in cirrhosis of the liver. Lancet 1971; 2: 504-10.
12. Ring-Larsen H. Renal blood flow in cirrhosis: relation to systemic and portal haemodynamics and liver function. Scand J Clin Lab Invest 1977; 37: 635-42.
13. Platt JF, Marn CS, Baliga PK, Ellis JH, Rubin JM, Merion RM. Renal dysfunction in hepatic disease: early identification with renal duplex Doppler US in patients who undergo liver transplantation. Radiology 1992; 183: 801-6.
14. Dagher L, Moore K. The hepatorenal syndrome. Gut 2001; 49: 729-37.
15. Arroyo V, Guevara M, Ginès P. Hepatorenal syndrome in cirrhosis: pathogenesis and treatment. Gastroenterology 2002; 122: 1658-76.
16. Schrier RW, Niederberger M, Weigert A, Ginès P. Peripheral arterial vasodilatation, determinant of functional spectrum of cirrhosis. Semin Liver Dis 1994; 14: 14-22.
17. Martin PY, Ginès P, Schrier RW. Nitric oxide as a mediator of hemodynamic abnormalities and sodium and water retention in cirrhosis. N Engl J Med 1998; 339: 533-41.
18. Wiest R, Groszmann RJ. Nitric oxide and portal hypertension: its role in the regulation of intrahepatic and splanchnic vascular resistance. Semin Liver Dis 1999; 19: 411-26.
19. Fernändez-Seara J, Prieto J, Quiroga J, et al. Systemic and regional hemodynamics in patients with liver cirrhosis and ascites with and without functional renal failure. Gastroenterology 1989; 97: 1304-12.
20. Maroto A, Ginès P, Arroyo V, et al. Brachial and femoral artery blood flow in cirrhosis: relationship to kidney dysfunction. Hepatology 1993; 17: 788-93.
21. Guevara M, Bru C, Ginès P, et al. Increased cerebrovascular resistance in cirrhotic patients with ascites. Hepatology 1998; 28: 39-44.
22. Sugano S, Yamamoto K, Atobe T, et al. Postprandial middle cerebral arterial vasoconstriction in cirrhotic patients. A placebo, controlled evaluation. J Hepatol 2001; 34: 373-7.
23. Ganne-Carrié N, Hadengue A, Mathurin P, et al. Hepatorenal syndrome. Long-term treatment with terlipressin as a bridge to liver transplantation. Dig Dis Sci 1996; 41: 1054-6.
24. Guevara M, Ginès P, Fernândez-Esparrach G, et al. Reversibility of hepatorenal syndrome by prolonged administration of ornipressin and plasma volume expansion. Hepatology 1998; 27: 35-41.
25. Hadengue A, Gadano A, Moreau R, et al. Beneficial effects of the 2-day administration of terlipressin in patients with cirrhosis and hepatorenal syndrome. J Hepatol 1998; 29: 565-70.
26. Le Moine O, el Nawar A, Jagodzinski R, et al. Treatment with terlipressin as a bridge to liver transplantation in a patient with hepatorenal syndrome. Acta Gastroenterol Belg 1998; 61: 268-70.
27. Gülberg V, Bilzer M, Gerbes AL. Long-term therapy and retreatment of hepatorenal syndrome type 1 with ornipressin and dopamine. Hepatology 1999; 30: 870-5.
28. Uriz J, Ginès P, Cardenas A, et al. Terlipressin plus albumin infusion is an effective and safe therapy of hepatorenal syndrome. J Hepatol 2000; 33: 43-8.
29. Mulkay JP, Louis H, Donckter V, et al. Long-term terlipressin administration improves renal function in cirrhotic patients with type 1 hepatorenal syndrome: a pilot study. Acta Gastroenterol Belg 2001; 64: 15-9.
30. Moreau R, Durand F, Poynard T, et al. Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome: a restrospective multicenter study. Gastroenterology 2002; 122: 923-30.
31. Ortega R, Ginès P, Uriz J, et al. Terlipressin therapy with and without albumin for patients with hepatorenal syndrome. Results of a prospective, non-randomized study. Hepatology 2002; 36: 941-8.
32. Halimi C, Bonnard P, Bernard B, et al. Effect of terlipressin (Glypressin) on hepatorenal syndrome in cirrhotic patients: results of a multicentre pilot study. Eur J Gastroenterol Hepatol 2002; 14: 153-8.
33. Colle I, Durand F, Pessione F, et al. Clinical course, predictive factors and prognosis in patients with cirrhosis and type 1 hepatorenal syndrome treated with terlipressin: a retrospective analysis. J Gastroenterol Hepatol 2002; 17: 882-8.
34. Alessandria C, Venon WD, Marzano A, et al. Renal failure in cirrhotic patients: role of terlipressin in clinical approach to hepatorenal syndrome type 2. Eur J Gastroenterol Hepatol 2002; 14: 1363-8.
35. Solanki P, Chawla A, Garg R, Gupta R, Jain M, Sarin SK. Beneficial effects of terlipressin in hepatorenal syndrome: A prospective, randomized placebo-controlled clinical trial. J Gastroenterol Hepatol 2003; 18: 152-6.
36. Restuccia T, Ortega R, Guevara M, et al. Effects of treatment of hepatorenal syndrome before transplantation on posttransplantation outcome. A case-control study. J Hepatol 2004; 40: 140-6.
37. 7 Moreau R. The growing evidence that renal function should be improved in patients with cirrhosis and hepatorenal syndrome before liver transplantation. J Hepatol 2004; 40: 159-61.
38. Angeli P, Volpin R, Gerunda G, et al. Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide. Hepatology 1999; 29: 1690-7.
39. Duvoux C, Zanditenas D, Hezode C, et al. Effects of nor-adrenalin and albumin in patients with type 1 hepatorenal syndrome: a pilot study. Hepatology 2002; 36: 374-80.
40. Guevara M, Ginès P, Bandi JC, et al. Transjugular intrahepatic portosystemic shunt in hepatorenal syndrome: effects on renal function and vasoactive systems. Hepatology 1998; 28: 416-22.
41. Mitzner SR, Stange J, Klammt S. Improvement of hepatorenal syndrome with extracorporeal albumin dialysis MARS, results of a prospective, randomized, controlled clinical trial. Liver Transpl 2000; 6: 277-86.